Dwaipayan Mukherjee
Overview
Explore the profile of Dwaipayan Mukherjee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Upadhyay R, Soni N, Vora A, Saraf A, Haldipur D, Mukherjee D, et al.
J Assoc Physicians India
. 2025 Feb;
73(2):68-77.
PMID: 39928002
The suppression of gastric acid secretion has long been the cornerstone of treatment for acid peptic disorders (APDs). Proton pump inhibitors (PPIs) have played a central role in managing these...
2.
Leary P, Le R, Panjabi S, Hartney J, Goyal A, Ward C, et al.
Am J Respir Crit Care Med
. 2025 Jan;
PMID: 39836217
Rationale: Guidelines recommend patients with pulmonary arterial hypertension (PAH) be referred to pulmonary hypertension (PH) centers, but little is known about where care is actually delivered in the United States...
3.
Reddy M, Cabalu T, de Zwart L, Ramsden D, Dowty M, Taskar K, et al.
Clin Pharmacol Ther
. 2024 Oct;
117(2):403-420.
PMID: 39422118
Physiologically-based pharmacokinetic (PBPK) modeling offers a viable approach to predict induction drug-drug interactions (DDIs) with the potential to streamline or reduce clinical trial burden if predictions can be made with...
4.
Mukherjee D, Collins M, Dylla D, Kaur J, Semizarov D, Martinez A, et al.
Infect Dis Ther
. 2023 Jul;
12(8):2057-2070.
PMID: 37470926
Introduction: An unsafe injection practice is one of the major contributors to new hepatitis C virus (HCV) infections; thus, people who inject drugs are a key population to prioritize to...
5.
Mukherjee D, Chen M, Shao X, Ju T, Shebley M, Marroum P
AAPS J
. 2023 Mar;
25(3):30.
PMID: 36949256
In lieu of large bioequivalence studies and exposing healthy postmenopausal women to additional drug exposure for elagolix coadministered with hormonal add-back therapy, physiologically based pharmacokinetic (PBPK) modeling was used with...
6.
Mukherjee D, Brackman D, Suleiman A, Zha J, Menon R, Salem A
J Clin Pharmacol
. 2022 Aug;
63(1):119-125.
PMID: 35996877
Venetoclax is an approved, orally bioavailable, B-cell lymphoma type 2 (BCL-2) inhibitor that is primarily metabolized by cytochrome P450 3A (CYP3A). Polypharmacy is common in patients undergoing treatment for hematological...
7.
Chu X, Prasad B, Neuhoff S, Yoshida K, Leeder J, Mukherjee D, et al.
Clin Pharmacol Ther
. 2022 May;
112(3):501-526.
PMID: 35561140
The role of membrane transporters on pharmacokinetics (PKs), drug-drug interactions (DDIs), pharmacodynamics (PDs), and toxicity of drugs has been broadly recognized. However, our knowledge of modulation of transporter expression and/or...
8.
Mukherjee D, Chiney M, Shao X, Ju T, Shebley M, Marroum P
Biopharm Drug Dispos
. 2022 Apr;
43(3):98-107.
PMID: 35405765
The aim of this analysis was to use a physiologically based pharmacokinetic (PBPK) model to predict the impact of changes in dissolution rates on elagolix exposures and define clinically relevant...
9.
Hariparsad N, Ramsden D, Taskar K, Badee J, Venkatakrishnan K, Reddy M, et al.
Clin Pharmacol Ther
. 2021 Dec;
112(4):770-781.
PMID: 34862964
The International Consortium for Innovation and Quality (IQ) Physiologically Based Pharmacokinetic (PBPK) Modeling Induction Working Group (IWG) conducted a survey across participating companies around general strategies for PBPK modeling of...
10.
Das D, Sit S, Khaowas A, Das C, Mukherjee D
Indian J Otolaryngol Head Neck Surg
. 2021 Oct;
73(4):467-473.
PMID: 34692459
Allergic rhinitis (AR) is one of the most common types of allergy worldwide. It has significant negative impact on the quality of life (QOL). One of the available causal treatments...